Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6403559

Title:C-kit ligand-based method for expanding peripheral blood cell levels
Inventors:Besmer, Peter; New York, NY, USA
Buck, Jochen; New York, NY, USA
Moore, Malcolm A. S.; New York, NY, USA
Nocka, Karl; Harvard, MA, USA
Summary:This invention describes a method for expanding peripheral blood cell levels ex vivo, via a novel pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in association with other hematopoietic factors. A pharmaceutically acceptable carrier is provided as well as methods of treating patients via the administration of the pharmaceutical composition. Further disclosed are combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. Also included are methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described, which may similarly be a small molecule. Antisense nucleic acids and therapeutics are disclosed, as well as methods for capitalizing upon the role of KL in germ cells, mast cells and melanocytes.
Abstract:A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6403559
Application Number:US1999000371261
Date Filed:10/08/1999
Date Published:11/06/2002
Assignee:Sloan-Kettering Institute for Cancer Research, New York, NY, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021